ClinicalTrials.gg
CompletedNCT04983368XanaMIA-DRUpdated Jan 23, 2025

A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers

A Phase 1/2 interventional study of Xanamem® 5 mg and Placebo in Mild Cognitive Impairment and Alzheimer's Disease, sponsored by Actinogen Medical. Completed at 5 sites in Australia. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-23.

Sponsored by Actinogen Medical · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Cognitive Dysfunction with a site in Australia — 12 open to participants now, 22 under way, 9 of them phase 3. Cognitive Dysfunction · Australia.

Enrollment
30th of 51
107 · median 167
Started
2021
with 6 others
Phase 1/2
2 of 57
none open now
Registered
32nd of 57
by date
Lead sponsor
3 of 57
Actinogen Medical

Among the 57 studies in Cognitive Dysfunction with a site in Australia, this one is the 30th largest by enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2021, is one of 2 in phase 1/2, and was the 32nd registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

12 of the 57 studies in Cognitive Dysfunction with a site in Australia are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Cognitive Dysfunction with a site in Australia, or all of them as a file.
02

Study summary

Xanamem® is being developed as a potential drug for Mild Cognitive Impairment in Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body. It is believed that reducing the level of cortisol will be a benefit in the treatment of Mild Cognitive Impairment in Alzheimer's disease.

The purpose of this study in older volunteers is to investigate the smallest dose of Xanamem® (5 mg or 10 mg) which works and to investigate which dose in this study will be used in the upcoming clinical trials in patients.

03

Conditions studied

  • Mild Cognitive Impairment
  • Alzheimer's Disease

Keywords

  • Cognitive Function
  • Healthy Volunteers
  • emestedastat
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 50 to 80
  2. 17.5 to \< 35 kg/m2, inclusive at the time of screening
  3. Mini-Mental State Score of ≥ 25 points at screening
  4. Must provide written

Exclusion criteria

Exclusion Criteria:

  1. Abnormalities in vital signs at screening or baseline
  2. abnormal hematology or biochemistry values, as determined by the investigator at screening and/or baseline.
  3. Previous clinically significant systemic illness or infection within the past 4 weeks prior to screening or baseline, as determined by the investigator
  4. Clinically significant abnormalities
  5. Use of tobacco- or nicotine-containing products in the past month or unwillingness to abstain during study participation
  6. Participation in another clinical study of a drug or device
  7. Known allergy to the study drug (Xanamem®) or any of the
  8. Subjects who are likely to be unable to comply with the study schedule and/ or subjects with an inability to communicate well with the investigator
  9. Positive testing for (HIV), surface antigen, or antibodies at screening
  10. Subjects with a history of drug abuse or addiction in the past 5 years.
  11. Evidence of alcohol abuse (defined as greater than 21 standard units per week for males and greater than 14 standard units per week for females)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Xanamem® 5 mg

    Oral Xanamem® capsules 5 mg, to be administered once daily

    Drug: Xanamem® 5 mg

  • Experimental
    Xanamem® 10 mg

    Oral Xanamem® capsules 10 mg, to be administered once daily

    Drug: Xanamem® 10 mg

  • Placebo comparator
    Placebo

    Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.

    Drug: Placebo

Interventions

  • DrugUE2343Studies of UE2343UE2343 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral Xanamem® ("UE2343") capsules 5 mg, administered orally once daily.

  • DrugPlacebo

    Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.

  • DrugUE2343Studies of UE2343UE2343 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral Xanamem® ("UE2343") capsules 10 mg, administered orally once daily.

06

What researchers measure

Primary outcomes

  1. Short-term efficacy: Assessment of changes of different doses of Xanamem® on cognition.

    Using a tailored Cogstate Neuropsychological Test Battery (NTB), changes from baseline, as well as composite scores based on a combination of these variables at each treatment visit \[Week 2, Week 4, Week 6 (End of Treatment), Week 10 (Follow-Up)\] will be analyzed.

    Time frame: Baseline, Week 2, Week 4, Week 6 (End of Treatment), Week 10 (Follow-Up)

  2. Assessment of safety and tolerability of different Xanamem® doses by the occurrence of Treatment-Emergent Adverse Events (TEAEs).

    The number, type, and severity of Treatment-Emergent Adverse Events (TEAEs) that are reported from Baseline to Follow-up Visit will be collected and evaluated.

    Time frame: 10 Weeks [Baseline to Week 10 Follow-Up (4 Weeks Post Last Dose of Study Drug)]

Secondary outcomes

  1. Short-term efficacy of different doses of Xanamem® on cognition

    Using the International Daily Digit Symbol Substitution Test-Symbols, to analyze changes from Screening to, Baseline, Week 2, Week 4, Week 6 (End of Treatment), Week 10 (Follow-Up).

    Time frame: Screening, Baseline, Week 2, Week 4, Week 6 (End of Treatment), Week 10 (Follow-Up)

07

Study locations

5 sites
  • Paratus Clinical Research Canberra
    Bruce, Australian Capital Territory 2617, Australia
  • Paratus Clinical Research Western Sydney
    Blacktown, New South Wales 2148, Australia
  • Paratus Clinical Research Central Coast
    Kanwal, New South Wales 2259, Australia
  • Paratus Clinical Research Brisbane
    Albion, Queensland 4010, Australia
  • USC Clinical Trials
    Sippy Downs, Queensland 4556, Australia
08

References and documents

Publications

  • Webster SP, McBride A, Binnie M, Sooy K, Seckl JR, Andrew R, Pallin TD, Hunt HJ, Perrior TR, Ruffles VS, Ketelbey JW, Boyd A, Walker BR. Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem). Br J Pharmacol. 2017 Mar;174(5):396-408. doi: 10.1111/bph.13699. Epub 2017 Jan 25. PubMed 28012176 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Feb 2022, 7 months.

Of 25 phase 1/2 interventional studies under Cognitive Dysfunction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2021
First posted
Jul 30, 2021
StartActual
Jun 30, 2021
Primary completionActual
Feb 11, 2022
CompletionActual
Feb 11, 2022
Last update
Jan 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04983368
Lead sponsor
Actinogen Medical
Collaborators
Avance Clinical Pty Ltd.
Responsible party
Sponsor
First posted
Jul 30, 2021
Start date
Jun 30, 2021
Primary completion
Feb 11, 2022
Completion
Feb 11, 2022
Last update
Jan 23, 2025

Study contacts

Miriam Roesner
study director · Actinogen Medical Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UE2343

Start the discussion